Rhythm Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: RYTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
90.78+1.14 (+1.27%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rhythm Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Rhythm Pharmaceuticals generated -$9.2 million of operating cash flow. That left free cash flow of -$9.2 million, a free-cash-flow margin of -12.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Rhythm Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -49.30M | -55.64M | -47.51M | -52.90M | -46.63M | -49.50M | -43.29M | -43.68M | -32.26M | -141.37M | -41.63M | -44.16M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 26.06M | 23.10M | 19.27M | 18.81M | 15.88M | 12.86M | 10.56M | 11.00M | 10.36M | 7.77M | 8.67M | 8.61M |
| Change in Working Capital | 10.65M | -17.45M | -10.00K | 8.35M | -899.00K | -8.01M | 5.42M | 3.79M | -3.20M | -3.38M | 8.91M | -2.12M |
| Operating Cash Flow | -9.15M | -44.19M | -25.39M | -26.62M | -23.31M | -40.35M | -18.84M | -25.21M | -29.08M | -40.74M | -29.38M | -29.25M |
| Capital Expenditures | — | — | — | — | — | — | — | — | — | — | 1.00K | -1.00K |
| Investing Cash Flow | 14.01M | 57.05M | 30.35M | -246.35M | 54.03M | 24.81M | 21.16M | -90.82M | -8.56M | 30.05M | 22.64M | -94.96M |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | 0 | — |
| Debt Repaid | -6.91M | -4.29M | -5.40M | -5.57M | -4.33M | -4.62M | -3.81M | -3.34M | -2.97M | -2.78M | -2.57M | -2.17M |
| Financing Cash Flow | -1.17M | -5.40M | -2.95M | 189.30M | -889.00K | 32.50M | 38.33M | 2.49M | 146.18M | 4.24M | 2.42M | 73.04M |
| Net Change in Cash | 3.48M | 7.92M | 2.07M | -83.36M | 29.55M | 16.96M | 41.62M | -114.14M | 108.24M | -6.52M | -4.51M | -51.09M |
| Free Cash Flow | -9.15M | -44.19M | -25.39M | -26.62M | -23.31M | -40.35M | -18.84M | -25.21M | -29.08M | -40.74M | -29.38M | -29.25M |
This table shows 12 quarterly periods of Rhythm Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RYTM's reporting calendar. What is a cash flow statement?